Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Stoppen en herbehandelen met etanercept bij nr-axSpA: resultaten van RE-EMBARK
jun 2023 | Spondyloartritis